Historique
Bulletin de Périodique
Addiction , Vol.113, n°12 - December 2018
Paru le :
01/12/2018
Année
2018
Page(s) :
2153-5324
Langue(s) :
Anglais
Note de contenu :
CONTENTS:
- Inconsistencies in the assumptions linking punitive sanctions and use of cannabis and new psychoactive substances in Europe [Editorial]. Hughes B., Matias J., Griffiths P., p. 2155-2157.
- Integrating smoking cessation care in alcohol and other drug treatment settings using an organizational change intervention: a systematic review. Skelton E., Tzelepis F., Shakeshaft A., Guillaumier A., McCrabb S., Bonevski B., p. 2158-2172.
- Probability discounting and gambling: a meta-analysis. Kyonka E.G.E., Schutte N.S., p. 2173-2181.
- A systematic review of the next-day effects of heavy alcohol consumption on cognitive performance. Gunn C., Mackus M., Griffin C., Munafo M.R., Adams S., p. 2182-2193.
- Women's role in the rise in drinking in Australia 1950-80: an age-period-cohort analysis of data from the Melbourne Collaborative Cohort Study. Stanesby O., Jayasekara H., Callinan S., Room R., English D., Giles G.G., et al., p. 2194-2202.
- Commentary on Stanesby et al. (2018): The importance of social change and trends in understanding increases in women's drinking in post-WWII Australia. Wilkinson C., McCalman J., Howe R., p. 2203-2204.
- Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Morley K.C., Luquin N., Baillie A., Fraser I., Trent R.J., Dore G., et al., p. 2205-2213.
- AUDIT-C and ICD codes as phenotypes for harmful alcohol use: association with ADH1B polymorphisms in two US populations. Justice A.C., Smith R.V., Tate J.P., McGinnis K., Xu K., Becker W.C., et al., p. 2214-2224.
- How dependent is the alcohol industry on heavy drinking in England? Bhattacharya A., Angus C., Pryce R., Holmes J., Brennan A., Meier P.S., p. 2225-2232.
- Commentary on Bhattacharya et al. (2018): Reliance of the alcohol industry on heavy drinkers makes case against industry involvement in alcohol policy. Boniface S., p. 2233-2234.
- After how many drinks does someone experience acute consequences - determining thresholds for binge drinking based on two event-level studies. Labhart F., Livingston M., Engels R., Kuntsche E., p. 2235-2244.
- Underestimation of alcohol consumption in cohort studies and implications for alcohol's contribution to the global burden of disease. Stockwell T., Zhao J., Sherk A., Rehm J., Shield K., Naimi T., p. 2245-2249.
- High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis. Socias M.E., Wood E., Lake S., Nolan S., Fairbairn N., Hayashi K., et al., p. 2250-2258.
- Commentary on Socias et al. (2018): Clinical research perspectives on cannabis use in opioid agonist treatment. Timko C., Cucciare M.A., p. 2259-2260.
- Gendered violence and overdose prevention sites: a rapid ethnographic study during an overdose epidemic in Vancouver, Canada. Boyd J., Collins A.B., Mayer S., Maher L., Kerr T., McNeil R., p. 2261-2270.
- EMS naloxone administration as non-fatal opioid overdose surveillance: 6-year outcomes in Marion County, Indiana. Ray B.R., Lowder E.M., Kivisto A.J., Phalen P., Gil H., p. 2271-2279.
- Mediators of the effect of nicotine pre-treatment on quitting smoking. Hajek P., Lewis S., Munafo M., Lindson N., Coleman T., Aveyard P., p. 2280-2289.
- Varenicline versus placebo for waterpipe smoking cessation: a double-blind randomized controlled trial. Dogar O., Zahid R., Mansoor S., Kanaan M., Ahluwalia J.S., Jawad M., et al., p. 2290-2299.
- A randomized usability assessment of simulated naloxone administration by community members. Eggleston W., Podolak C., Sullivan R.W., Pacelli L., Keenan M., Wojcik S., p. 2300-2304.
- Burroughs' 'Letter from a master addict to dangerous drugs': a forgotten classic. Darke S., Farrell M., p. 2305-2308.
- Trends and characteristics of naloxone therapy reported to US poison centers. Rege S.V., Ngo D.A., Ait-Daoud N., Sharma S., Verplancken E., Holstege C.P., p. 2309-2315.
- Commentary on Rege et al. (2018): Naloxone reports to US poison centers highlight overdose prevention opportunities. Oliva E.M., Bounthavong M., p. 2316-2317.
- Reaction to 'Integrating smoking cessation care in alcohol and other drug treatment settings using an organizational change intervention: a systematic review' by Skelton et al. (2018). Van de Graaf R.C., Veldman K., Anthonio G.G., p. 2318.
- Inconsistencies in the assumptions linking punitive sanctions and use of cannabis and new psychoactive substances in Europe [Editorial]. Hughes B., Matias J., Griffiths P., p. 2155-2157.
- Integrating smoking cessation care in alcohol and other drug treatment settings using an organizational change intervention: a systematic review. Skelton E., Tzelepis F., Shakeshaft A., Guillaumier A., McCrabb S., Bonevski B., p. 2158-2172.
- Probability discounting and gambling: a meta-analysis. Kyonka E.G.E., Schutte N.S., p. 2173-2181.
- A systematic review of the next-day effects of heavy alcohol consumption on cognitive performance. Gunn C., Mackus M., Griffin C., Munafo M.R., Adams S., p. 2182-2193.
- Women's role in the rise in drinking in Australia 1950-80: an age-period-cohort analysis of data from the Melbourne Collaborative Cohort Study. Stanesby O., Jayasekara H., Callinan S., Room R., English D., Giles G.G., et al., p. 2194-2202.
- Commentary on Stanesby et al. (2018): The importance of social change and trends in understanding increases in women's drinking in post-WWII Australia. Wilkinson C., McCalman J., Howe R., p. 2203-2204.
- Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Morley K.C., Luquin N., Baillie A., Fraser I., Trent R.J., Dore G., et al., p. 2205-2213.
- AUDIT-C and ICD codes as phenotypes for harmful alcohol use: association with ADH1B polymorphisms in two US populations. Justice A.C., Smith R.V., Tate J.P., McGinnis K., Xu K., Becker W.C., et al., p. 2214-2224.
- How dependent is the alcohol industry on heavy drinking in England? Bhattacharya A., Angus C., Pryce R., Holmes J., Brennan A., Meier P.S., p. 2225-2232.
- Commentary on Bhattacharya et al. (2018): Reliance of the alcohol industry on heavy drinkers makes case against industry involvement in alcohol policy. Boniface S., p. 2233-2234.
- After how many drinks does someone experience acute consequences - determining thresholds for binge drinking based on two event-level studies. Labhart F., Livingston M., Engels R., Kuntsche E., p. 2235-2244.
- Underestimation of alcohol consumption in cohort studies and implications for alcohol's contribution to the global burden of disease. Stockwell T., Zhao J., Sherk A., Rehm J., Shield K., Naimi T., p. 2245-2249.
- High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis. Socias M.E., Wood E., Lake S., Nolan S., Fairbairn N., Hayashi K., et al., p. 2250-2258.
- Commentary on Socias et al. (2018): Clinical research perspectives on cannabis use in opioid agonist treatment. Timko C., Cucciare M.A., p. 2259-2260.
- Gendered violence and overdose prevention sites: a rapid ethnographic study during an overdose epidemic in Vancouver, Canada. Boyd J., Collins A.B., Mayer S., Maher L., Kerr T., McNeil R., p. 2261-2270.
- EMS naloxone administration as non-fatal opioid overdose surveillance: 6-year outcomes in Marion County, Indiana. Ray B.R., Lowder E.M., Kivisto A.J., Phalen P., Gil H., p. 2271-2279.
- Mediators of the effect of nicotine pre-treatment on quitting smoking. Hajek P., Lewis S., Munafo M., Lindson N., Coleman T., Aveyard P., p. 2280-2289.
- Varenicline versus placebo for waterpipe smoking cessation: a double-blind randomized controlled trial. Dogar O., Zahid R., Mansoor S., Kanaan M., Ahluwalia J.S., Jawad M., et al., p. 2290-2299.
- A randomized usability assessment of simulated naloxone administration by community members. Eggleston W., Podolak C., Sullivan R.W., Pacelli L., Keenan M., Wojcik S., p. 2300-2304.
- Burroughs' 'Letter from a master addict to dangerous drugs': a forgotten classic. Darke S., Farrell M., p. 2305-2308.
- Trends and characteristics of naloxone therapy reported to US poison centers. Rege S.V., Ngo D.A., Ait-Daoud N., Sharma S., Verplancken E., Holstege C.P., p. 2309-2315.
- Commentary on Rege et al. (2018): Naloxone reports to US poison centers highlight overdose prevention opportunities. Oliva E.M., Bounthavong M., p. 2316-2317.
- Reaction to 'Integrating smoking cessation care in alcohol and other drug treatment settings using an organizational change intervention: a systematic review' by Skelton et al. (2018). Van de Graaf R.C., Veldman K., Anthonio G.G., p. 2318.
Cote :
Abonnement
Dépouillements
Ajouter le résultat à votre sélection![Inconsistencies in the assumptions linking punitive sanctions and use of cannabis and new psychoactive substances in Europe [Editorial]](https://bdoc.ofdt.fr/img_cache/pmb_ofdt_record_81210.webp?v=1771254041)
B. HUGHES ;
J. MATIAS ;
P. GRIFFITHS
|
2018
Dans Addiction (Vol.113, n°12, December 2018) Article : Périodique
Dans Addiction (Vol.113, n°12, December 2018) Article : Périodique
Changing the severity of statutory penalties for cannabis use offences does not appear to have a consistent impact on cannabis use by young adults, and new policy responses to the proliferation of new psychoactive substances within European coun[...]
A. BHATTACHARYA ;
C. ANGUS ;
R. PRYCE ;
J. HOLMES ;
A. BRENNAN ;
P. S. MEIER
|
2018
Dans Addiction (Vol.113, n°12, December 2018) Article : Périodique
Dans Addiction (Vol.113, n°12, December 2018) Article : Périodique
AIMS: To understand the extent of the alcohol industry's financial dependence on drinking above government low-risk guidelines in England.
DESIGN: Scenario modelling using descriptive analyses of pooled data from the 2013 and 2014 waves of two[...]
F. LABHART ;
M. LIVINGSTON ;
R. ENGELS ;
E. KUNTSCHE
|
2018
Dans Addiction (Vol.113, n°12, December 2018) Article : Périodique
Dans Addiction (Vol.113, n°12, December 2018) Article : Périodique
BACKGROUND AND AIMS: The threshold of 4+/5+ drinks per occasion has been used for decades in alcohol research to distinguish between non-risky versus risky episodic drinking. However, no study has assessed the validity of this threshold using ev[...]
T. STOCKWELL ;
J. ZHAO ;
A. SHERK ;
J. REHM ;
K. SHIELD ;
T. NAIMI
|
2018
Dans Addiction (Vol.113, n°12, December 2018) Article : Périodique
Dans Addiction (Vol.113, n°12, December 2018) Article : Périodique
BACKGROUND AND AIMS: Estimated alcohol consumption from national self-report surveys is often only 30-40% of official estimates based on sales or taxation data. Global burden of disease (GBD) estimates for alcohol adjust survey estimates up to 8[...]
S. V. REGE ;
D. A. NGO ;
N. AIT-DAOUD ;
S. SHARMA ;
E. VERPLANCKEN ;
C. P. HOLSTEGE
|
2018
Dans Addiction (Vol.113, n°12, December 2018) Article : Périodique
Dans Addiction (Vol.113, n°12, December 2018) Article : Périodique
BACKGROUND AND AIMS: In the United States, access to naloxone has been expanded as a measure to address growing opioid overdose mortality. The study aimed to describe the national trends in naloxone use as reported to the US poison centers (PCs)[...]